The AIDS Clinical Trials Group (ACTG) will launch the first Phase II trial of VRC07-523LS, a broadly neutralizing antibody engineered by the NIH/DAIDS Vaccine Research Center, and long-acting cabotegravir in adults who have achieved durable viral suppression. Dr. Taiwo co-leads the study with Dr. Pablo Tebas, Professor of Medicine at the University of Pennsylvania. Read the full announcement in NIAID Now.

Dr. Taiwo directs the Clinical Sciences Core and is the Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases at Northwestern University Feinberg School of Medicine.

More information about this trial, A5357, is available at under study identifier NCT03739996. Contact Baiba Berzins if you are interested in joining this study at Northwestern University or referring eligible patients.